Log In
BCIQ
Print this Print this
 

Jext

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionAdrenaline pen
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsEmergency treatment of severe acute allergic reactions
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$81.4M

$40.7M

$40.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/09/2015

Undisclosed

Undisclosed

Undisclosed

01/28/2011

$81.4M

$40.7M

$40.7M

Get a free BioCentury trial today